TY  - JOUR
AU  - Kuo, Phillip H
AU  - Yoo, Don C
AU  - Avery, Ryan
AU  - Seltzer, Marc
AU  - Calais, Jeremie
AU  - Nagarajah, James
AU  - Weber, Wolfgang A
AU  - Fendler, Wolfgang P
AU  - Hofman, Michael S
AU  - Krause, Bernd J
AU  - Brackman, Marcia
AU  - Kpamegan, Euloge
AU  - Ghebremariam, Samson
AU  - Benson, Taylor
AU  - Catafau, Ana M
AU  - Kendi, Ayse T
TI  - A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy.
JO  - Journal of nuclear medicine
VL  - 64
IS  - 8
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-01047
SP  - 1259-1265
PY  - 2023
N1  - 2023 Aug;64(8):1259-1265
AB  - 68Ga-gozetotide (68Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)-positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with 177Lu-vipivotide tetraxetan (177Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, 68Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77
KW  - PET/CT (Other)
KW  - PSMA (Other)
KW  - prostate cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37230533
DO  - DOI:10.2967/jnumed.122.265077
UR  - https://inrepo02.dkfz.de/record/276245
ER  -